Cancers
Treatment Sequencing of CDK4/6 Inhibitors in Bone-Only Hormone Receptor-Positive Metastatic Breast Cancer: Multi-Center Real-World Data Revealing a Numerical Trend Favoring Later-Line Use
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the gold standard in the first-line treatment of hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). However, the optimal timing of CDK4/6i initiation in patients with bone-only disease (BoD) remains a matter of clinical discussion. This multicenter retrospective study evaluated the impact of CDK4/6i treatment line (first-line vs. second-or-later-line) on progression-free survival (PFS) a …